News & Updates

Treatment with prehospital pulse-dose glucocorticoid does not appear to shrink final infarct size in patients with ST-segment elevation myocardial infarction (STEMI) after 3 months, according to a study.

Combining verinurad with allopurinol does not appear to boost oxygen uptake or improve symptoms in heart failure with preserved ejection fraction (HFpEF), despite yielding significant reductions in serum uric acid (SUA) levels, according to a phase II study.

A high total dose of primaquine outperforms a low dose at preventing the recurrence of Plasmodium vivax malaria in children, although it comes with more serious adverse events, according to the results of a meta-analysis.

A post hoc analysis of a phase IV study presented at EADV 2024 underscores the ability of the fourth-generation retinoid trifarotene to reduce atrophic acne scars across all skin types, with a more profound effect among individuals with higher baseline acne and acne scarring severity.

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.